There are currently 2668 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Confocal Laser Endomicroscopy As an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
NCT03492151
Recruiting
The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtained during the clinic visit or prior to their EUS. EUS-guided nCLE imaging is first performed (B) followed by EUS-guided FNA and aspiration of cyst fluid. The cyst fluid is analyzed for CEA and cytology. As per institutional standard of care, the cyst fluid is a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Pancreatic Cyst
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Dana-Farber Cancer Institute /ID# 249529, Boston, Massachusetts
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Poly-omic Predictors of Symptom Duration and Recovery for Adolescent Concussion
NCT04582682
Recruiting
The purpose of this study is to identify changes in salivary micro ribonucleic acid (miRNA) levels that are predictive of symptom duration and character following mild traumatic brain injury (mTBI) in children.
Gender:
ALL
Ages:
Between 13 years and 18 years
Trial Updated:
03/03/2025
Locations: Boston Children's Hosptial, Boston, Massachusetts
Conditions: Concussion, Mild
Register for Updates
A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition
NCT06581146
Recruiting
XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition. Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the live... Read More
Gender:
MALE
Ages:
17 years and below
Trial Updated:
03/03/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: X-Linked Myotubular Myopathy
Register for Updates
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618
Recruiting
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
03/01/2025
Locations: Brigham and Womens Hosp Harvard Med School, Boston, Massachusetts
Conditions: C3G
Register for Updates
Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism
NCT04648969
Recruiting
The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Hypogonadotropic Hypogonadism
Register for Updates
Longitudinal Study of the Porphyrias
NCT01561157
Recruiting
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.
Gender:
ALL
Ages:
1 minute and above
Trial Updated:
02/28/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Acute Porphyrias, Cutaneous Porphyrias
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Boston, Massachusetts +1 locations
Conditions: Neoplasms
Register for Updates
Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
NCT04683250
Recruiting
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Register for Updates
Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes
NCT06236607
Recruiting
Minoritized individuals with type 1 diabetes (T1D) have approximately 2% higher average A1c levels and twice the rate of hospitalizations, complications, and mortality as their white counterparts. However, the efficacy trials establishing the benefits of hybrid closed loop (HCL) pump therapy in T1D have been in more socially advantaged and predominantly non-Hispanic white patients. Use of this technology by individuals with T1D from underserved communities remains very low. The investigators pl... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/28/2025
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 1, Diabetes Complications
Register for Updates
A Study of PHN-010 in Patients with Advanced Solid Tumors
NCT06457997
Recruiting
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Advanced Solid Tumor, Advanced Cancer
Register for Updates
High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
NCT04331639
Recruiting
The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.
Gender:
ALL
Ages:
Between 5 years and 25 years
Trial Updated:
02/27/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency
Register for Updates